Advanced search
Publication Cover
Infection and Drug Resistance Volume 14, 2021 - Issue
Submit an article Journal homepage
103
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Acquired Resistance to Isoniazid During Isoniazid Monotherapy in a Subject with Latent Infection Following Household Rifampicin-Resistant Tuberculosis Contact: A Case Report

Tsung-Lun Li1 Department of Internal Medicine, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan
,
Tai-Hua Chan2 Taiwan Centers for Disease Control, Taipei, Taiwan
,
Cheng-Hui Wang3 Pulmonary Research Center, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan;4 Department of Laboratory Medicine, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan;5 School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
,
Ruwen Jou2 Taiwan Centers for Disease Control, Taipei, Taiwan;6 Institute of Microbiology and Immunology, National Yang-Ming Chiao Tung University, Taipei, Taiwan
,
Ming-Chih Yu1 Department of Internal Medicine, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan;3 Pulmonary Research Center, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan;7 Schools of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan
,
Denise Utami Putri3 Pulmonary Research Center, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan
,
Chih-Hsin Lee1 Department of Internal Medicine, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan;3 Pulmonary Research Center, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan;8 Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, TaiwanCorrespondence[email protected] [email protected]
&
Yi-Hsien Lin3 Pulmonary Research Center, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan
 show all
Pages 1505-1509 | Published online: 20 Apr 2021

References

  • World Health Organization. Latent TB infection: updated and consolidated guidelines for programmatic management; 2018.
  • Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152. doi:10.1371/journal.pmed.100215227780211
  • World Health Organization. Global tuberculosis report 2019; 2019.
  • Flynn AG, Aiona K, Haas MK, Reves R, Belknap R. Clinical characteristics of active tuberculosis diagnosed after starting treatment for latent tuberculosis infection. Clin Infect Dis. 2019. doi:10.1093/cid/ciz1157
  • Drain PK, Bajema KL, Dowdy D, et al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection. Clin Microbiol Rev. 2018;31(4):e00021–18. doi:10.1128/CMR.00021-18
  • Taiwan Centers for Disease Control. Taiwan Tuberculosis Control Report 2019. 2020. Available from: https://www.cdc.gov.tw/File/Get/eohpjs5F-9obJG4sMlmHBw. Accessed January 24, 2021.
  • Chiang C-Y. Taiwan Guidelines for TB Diagnosis & Treatment. Vol. 6. Taiwan Centers for Disease Control; 2017.
  • Durairaj DR, Shanmughavel P. In silico drug design of thiolactomycin derivatives against Mtb-KasA enzyme to inhibit multidrug resistance of mycobacterium tuberculosis. Interdiscip Sci. 2019;11(2):215–225. doi:10.1007/s12539-017-0257-028856604
  • Dean AS, Zignol M, Cabibbe AM, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: a multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1):e1003008. doi:10.1371/journal.pmed.100300831961877
  • Fox GJ, Dobler CC, Marais BJ, Denholm JT. Preventive therapy for latent tuberculosis infection-the promise and the challenges. Int J Infect Dis. 2017;56:68–76. doi:10.1016/j.ijid.2016.11.00627872018
  • Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–2166. doi:10.1056/NEJMoa110487522150035
  • Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12(5):744–751. doi:10.3201/eid1205.05068116704830
  • Cohen T, van Helden PD, Wilson D, et al. Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control. Clin Microbiol Rev. 2012;25(4):708–719. doi:10.1128/CMR.00021-1223034327
  • Mathur M, Badhan RK, Kumari S, Kaur N, Gupta S. Radiological manifestations of pulmonary tuberculosis - a Comparative Study between Immunocompromised and Immunocompetent Patients. J Clin Diagn Res. 2017;11(9):TC06–TC09. doi:10.7860/JCDR/2017/28183.10535
  • Eisenberg RL, Pollock NR. Low yield of chest radiography in a large tuberculosis screening program. Radiology. 2010;256(3):998–1004. doi:10.1148/radiol.1010048520720079
  • Delogu G, Goletti D. The spectrum of tuberculosis infection: new perspectives in the era of biologics. J Rheumatol Suppl. 2014;91:11–16. doi:10.3899/jrheum.14009724788995

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.